Sirolimus eluting stent implantation for patients with multivessel disease: rationale for the arterial revascularisation therapies study part II (ARTS II)

Open Access
Publisher Website
Google Scholar
Abstract
The sirolimus eluting stent received Conformité Européenne mark approval in April 2002, since when it has been available for routine use in Europe. From 16 April 2002, it has been the policy of our institution to utilise sirolimus eluting stents as the device of choice for all percutaneous coronary interventions, as part of the RESEARCH (rapamycin-eluting stent evaluated at Rotterdam Cardiology Hospital) study, which is a single centre registry conducted with the main purpose of evaluating the efficacy of sirolimus eluting stent implantation in the “real world”.5